Multiple Myeloma: Planning a Continuum of Care in 2020

home / peer-exchange / multiple-myeloma-planning-a-continuum-of-care-in-2020

EP. 1: Frontline Triplet Therapies in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 2: Tolerability of Triplet Therapy in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 3: Transplant-Ineligible Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 4: Treating Transplant-Eligible and -Ineligible MM

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 5: The Role of Transplant in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 6: MRD Monitoring in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 7: Maintenance Therapy Approaches in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

$Management of Relapsed/Refractory Multiple Myeloma$

EP. 8: Management of Relapsed/Refractory Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 9: Daratumumab With Carfilzomib in Frontline Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

$Lenalidomide-Refractory Multiple Myeloma$

EP. 10: Lenalidomide-Refractory Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

$BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma$

EP. 11: BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 12: BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 13: BCMA-Targeted Therapies in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 14: Using Antibody-Drug Conjugates in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 15: Development of CAR T Cells in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 16: Differentiating among CAR T Products for Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 17: Bispecific Antibodies for Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

EP. 18: Future of BCMA-Targeted Therapies in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital
Natalie S. Callander, MD, University of Washington Carbone Cancer Center

July 17th 2020

Latest Conference Coverage

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512